Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADUS NYSE:ARDT NASDAQ:PSNL NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADUSAddus HomeCare$113.10-2.2%$112.13$88.96▼$136.72$2.12B0.85181,826 shs117,326 shsARDTArdent Health$12.78+0.9%$12.36$10.10▼$20.72$1.82B0.3369,650 shs253,463 shsPSNLPersonalis$4.85+0.8%$5.71$2.83▼$7.79$433.63M1.761.03 million shs827,583 shsVCYTVeracyte$30.62+1.7%$27.10$22.61▼$47.32$2.39B2.071.25 million shs1.23 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADUSAddus HomeCare-2.22%-2.08%+5.74%+0.84%-13.01%ARDTArdent Health+0.38%+0.81%+23.83%-13.13%-33.79%PSNLPersonalis+0.83%+1.46%-12.93%-4.15%-7.09%VCYTVeracyte+1.69%+7.03%+25.90%+13.49%+1.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADUSAddus HomeCare4.8154 of 5 stars3.52.00.05.02.22.53.1ARDTArdent Health3.5779 of 5 stars3.40.00.00.03.60.03.1PSNLPersonalis4.0352 of 5 stars3.51.00.04.22.62.50.6VCYTVeracyte2.9964 of 5 stars3.40.00.04.32.80.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADUSAddus HomeCare 3.00Buy$138.8922.80% UpsideARDTArdent Health 2.70Moderate Buy$19.5653.08% UpsidePSNLPersonalis 3.00Buy$7.4252.92% UpsideVCYTVeracyte 2.70Moderate Buy$40.9033.57% UpsideCurrent Analyst Ratings BreakdownLatest PSNL, VCYT, ARDT, and ADUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025ADUSAddus HomeCareStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$140.009/2/2025ADUSAddus HomeCareUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$145.008/22/2025ADUSAddus HomeCareRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$133.00 ➝ $134.008/19/2025ADUSAddus HomeCareBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderweight ➝ Underweight$83.00 ➝ $109.008/11/2025ARDTArdent HealthJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$18.00 ➝ $15.008/8/2025VCYTVeracyteMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetUnderweight ➝ Underweight$28.008/7/2025ARDTArdent HealthKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $20.008/6/2025PSNLPersonalisBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$6.008/6/2025ADUSAddus HomeCareTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$135.00 ➝ $139.008/6/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.507/16/2025ADUSAddus HomeCareJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$150.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADUSAddus HomeCare$1.15B1.81$5.29 per share21.37$55.44 per share2.04ARDTArdent Health$5.97B0.31$2.56 per share5.00$11.52 per share1.11PSNLPersonalis$84.61M5.08N/AN/A$2.15 per share2.26VCYTVeracyte$445.76M5.40$1.05 per share29.26$15.52 per share1.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADUSAddus HomeCare$73.60M$4.5324.9721.101.756.51%9.39%6.86%11/3/2025 (Estimated)ARDTArdent Health$210.34M$1.817.066.525.614.11%16.66%5.18%11/5/2025 (Estimated)PSNLPersonalis-$81.28M-$1.28N/AN/AN/A-113.70%-47.57%-35.05%11/5/2025 (Estimated)VCYTVeracyte$24.14M$0.3392.7942.53N/A5.50%6.07%5.53%11/5/2025 (Estimated)Latest PSNL, VCYT, ARDT, and ADUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ARDTArdent Health$0.30$0.52+$0.22$0.52$1.54 billion$1.65 billion8/5/2025Q2 2025PSNLPersonalis-$0.25-$0.23+$0.02-$0.23$20.12 million$17.20 million8/4/2025Q2 2025ADUSAddus HomeCare$1.45$1.49+$0.04$1.20$345.71 million$349.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADUSAddus HomeCareN/AN/AN/AN/AN/AARDTArdent HealthN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADUSAddus HomeCare0.171.741.74ARDTArdent Health0.662.132.00PSNLPersonalisN/A6.095.92VCYTVeracyteN/A5.435.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADUSAddus HomeCare95.35%ARDTArdent HealthN/APSNLPersonalis61.91%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipADUSAddus HomeCare4.50%ARDTArdent Health1.70%PSNLPersonalis3.80%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADUSAddus HomeCare49,70318.43 million17.60 millionOptionableARDTArdent Health24,900143.11 million140.67 millionOptionablePSNLPersonalis40088.68 million85.31 millionOptionableVCYTVeracyte79078.67 million77.57 millionOptionablePSNL, VCYT, ARDT, and ADUS HeadlinesRecent News About These CompaniesMagnetar Financial LLC Invests $651,000 in Veracyte, Inc. $VCYTSeptember 3 at 5:25 AM | marketbeat.comTrexquant Investment LP Sells 10,790 Shares of Veracyte, Inc. $VCYTSeptember 3 at 5:12 AM | marketbeat.comHsbc Holdings PLC Buys 10,618 Shares of Veracyte, Inc. $VCYTSeptember 2 at 3:58 AM | marketbeat.comRafferty Asset Management LLC Has $3.29 Million Stock Position in Veracyte, Inc. $VCYTSeptember 1 at 4:44 AM | marketbeat.comNorthern Trust Corp Trims Stake in Veracyte, Inc. $VCYTSeptember 1 at 3:51 AM | marketbeat.comDriehaus Capital Management LLC Purchases 167,604 Shares of Veracyte, Inc. $VCYTAugust 31, 2025 | marketbeat.comRussell Investments Group Ltd. Sells 28,644 Shares of Veracyte, Inc. $VCYTAugust 31, 2025 | marketbeat.comNext Century Growth Investors LLC Lowers Stake in Veracyte, Inc. $VCYTAugust 30, 2025 | marketbeat.comVeracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceAugust 29, 2025 | businesswire.comVeracyte reports Phase 3 STAMPEDE trial finding published in CellAugust 28, 2025 | msn.comVeracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate CancerAugust 27, 2025 | businesswire.comVirtus Advisers LLC Acquires Shares of 36,230 Veracyte, Inc. $VCYTAugust 27, 2025 | marketbeat.com76,342 Shares in Veracyte, Inc. $VCYT Acquired by Campbell & CO Investment Adviser LLCAugust 27, 2025 | marketbeat.comInvesco Ltd. Lowers Position in Veracyte, Inc. $VCYTAugust 27, 2025 | marketbeat.comVeracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer TestAugust 26, 2025 | finance.yahoo.comVeracyte: Q2 Earnings Brings My Position Out Of MothballsAugust 26, 2025 | seekingalpha.comIs the Options Market Predicting a Spike in Veracyte Stock?August 25, 2025 | zacks.comHow Investors May Respond To Veracyte (VCYT) Earnings Upgrades and Spotlight as a Momentum StockAugust 24, 2025 | finance.yahoo.comAdvantage Alpha Capital Partners LP Has $779,000 Stake in Veracyte, Inc. $VCYTAugust 24, 2025 | marketbeat.comWellington Management Group LLP Has $114.25 Million Stake in Veracyte, Inc. $VCYTAugust 24, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $21.96 Million Stake in Veracyte, Inc. $VCYTAugust 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePSNL, VCYT, ARDT, and ADUS Company DescriptionsAddus HomeCare NASDAQ:ADUS$113.10 -2.57 (-2.22%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$113.13 +0.03 (+0.03%) As of 09/3/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.Ardent Health NYSE:ARDT$12.78 +0.11 (+0.85%) Closing price 09/3/2025 03:59 PM EasternExtended Trading$12.78 +0.01 (+0.05%) As of 09/3/2025 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.Personalis NASDAQ:PSNL$4.85 +0.04 (+0.83%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$4.72 -0.13 (-2.58%) As of 09/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.Veracyte NASDAQ:VCYT$30.62 +0.51 (+1.69%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$30.62 +0.00 (+0.02%) As of 09/3/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
